Nomad Bioscience signs licensing agreement with Bayer and Icon Genetics

The agreement provides Nomad access to Icon’s proprietary technology platforms, including its transient expression technology magnICON, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The agreement provides Nomad with the strategically needed freedom to operate in its core business areas. The financial terms of the agreement have not been disclosed.

Yuri Gleba, founder of Nomad Bioscience, said: “Icon Genetics’s proprietary gene transfer systems provide a broad solution to the upstream part of manufacturing, and combined with Nomad downstream technologies, they should result in a superior fully integrated process for most of our intended product candidates.”

Detlef Wollweber, managing director of Bayer Innovation, said: “Icon has developed new generation production platforms that are by far more effective than those commercialized today. Since our own strategic focus is on proprietary biopharmaceuticals, we were looking for a partner who could best apply our proprietary expression methods to other new classes of products.”